In this CEP Magazine article, Sidley partners Holly J. Gregory and Paul E. Kalb, MD, the co-chair of Sidley’s Executive Compensation and Corporate Governance practice and the global head of Sidley’s Healthcare and FDA Group, respectively, discuss the considerations evaluating whether highly regulated public companies should have board-level compliance committees.
Copyright 2021 CEP Magazine, a publication of the Society of Corporate Compliance and Ethics (SCCE).
